SARS-CoV-1 Spike Protein (E7C5Y) Rabbit mAb #26769
- WB
Supporting Data
| REACTIVITY | Vir |
| SENSITIVITY | Transfected Only |
| MW (kDa) | 200 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- Vir-Virus
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
SARS-CoV-1 Spike Protein (E7C5Y) Rabbit mAb recognizes transfected levels of total SARS-CoV-1 spike protein. It does not cross-react with spike proteins from SARS-CoV-2 or MERS coronaviruses.
Species Reactivity:
Virus
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of SARS-CoV-1 spike protein.
Background
The cause of the SARS epidemic in 2003 was a novel pathogenic coronavirus, originally termed SARS-CoV (severe acute respiratory syndrome coronavirus) (1). Following the 2019 emergence of SARS-CoV-2 and the COVID-19 pandemic, SARS-CoV is now often referred to as SARS-CoV-1. SARS-CoV-1 is a member of the Coronaviridae family of viruses (2). The genome of SARS-CoV-1 is similar to other coronaviruses, and is comprised of four key structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (3). Coronavirus spike proteins are class I fusion proteins that harbor an ectodomain, a transmembrane domain, and an intracellular tail (4,5). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at the S1/S2 junction, with possible secondary cleavage occurring at a downstream site (S2/S2’) (6). S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (3,5). As with SARS-CoV-2, the SARS-CoV-1 spike protein utilizes the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (7-9). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (10,11).
- Xu, R.H. et al. (2004) Emerg Infect Dis 10, 1030-7.
- Zhou, P. et al. (2020) Nature 579, 270-273.
- Tortorici, M.A. and Veesler, D. (2019) Adv Virus Res 105, 93-116.
- Li, F. et al. (2006) J Virol 80, 6794-800.
- Li, F. (2016) Annu Rev Virol 3, 237-261.
- Belouzard, S. et al. (2009) Proc Natl Acad Sci U S A 106, 5871-6.
- Shang, J. et al. (2020) Nature 581, 221-224.
- Wrapp, D. et al. (2020) Science 367, 1260-1263.
- Yan, R. et al. (2020) Science 367, 1444-1448.
- Yuan, Y. et al. (2017) Nat Commun 8, 15092.
- Amanat, F. and Krammer, F. (2020) Immunity 52, 583-589.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.